[HTML][HTML] Pasireotide in the personalized treatment of acromegaly
M Puig-Domingo, I Bernabéu, A Picó… - Frontiers in …, 2021 - frontiersin.org
The delay in controlling the disease in patients who do not respond to first-line treatment
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …
[HTML][HTML] Epithelial–mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly
Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss
their phenotype and acquire mesenchymal traits, including increased migratory and invasive …
their phenotype and acquire mesenchymal traits, including increased migratory and invasive …
[HTML][HTML] Data mining analyses for precision medicine in acromegaly: a proof of concept
Predicting which acromegaly patients could benefit from somatostatin receptor ligands
(SRL) is a must for personalized medicine. Although many biomarkers linked to SRL …
(SRL) is a must for personalized medicine. Although many biomarkers linked to SRL …
[HTML][HTML] Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly
J Rymuza, P Kober, N Rusetska, BJ Mossakowska… - Cells, 2022 - mdpi.com
Acromegaly results from growth hormone hypersecretion, predominantly caused by a
somatotroph pituitary neuroendocrine tumor (PitNET). Acromegaly-causing tumors are …
somatotroph pituitary neuroendocrine tumor (PitNET). Acromegaly-causing tumors are …
[HTML][HTML] Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study
AM Berton, N Prencipe, L Bertero, M Baldi… - Journal of Clinical …, 2022 - mdpi.com
Approximately 60% of acromegaly patients are not adequately controlled by first-generation
somatostatin receptor ligands. This multicenter retrospective study aimed to identify the most …
somatostatin receptor ligands. This multicenter retrospective study aimed to identify the most …
[HTML][HTML] Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Introduction We previously described that a short version of the acute octreotide test (sAOT)
can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients …
can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients …
[HTML][HTML] Implications of heterogeneity of epithelial-mesenchymal states in acromegaly therapeutic pharmacologic response
Acromegaly is caused by excess growth hormone (GH) produced by a pituitary tumor. First-
generation somatostatin receptor ligands (SRLs) are the first-line treatment. Several studies …
generation somatostatin receptor ligands (SRLs) are the first-line treatment. Several studies …
[HTML][HTML] Резистентность к медикаментозному лечению акромегалии и пути ее преодоления
ОО Голоунина, ЛК Дзеранова… - Ожирение и …, 2021 - cyberleninka.ru
Акромегалия-тяжелое инвалидизирующее нейроэндокринное заболевание,
обусловленное длительной избыточной продукцией соматотропного гормона и …
обусловленное длительной избыточной продукцией соматотропного гормона и …
[HTML][HTML] Resistance to drug treatment of acromegaly and ways to overcome it
OO Golounina, LK Dzeranova… - Obesity and …, 2021 - omet-endojournals.ru
Acromegaly is a severe disabling neuroendocrine disease caused by hypersecretion of
growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The problem of resistance to …
growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The problem of resistance to …